摘要:
Fluorenecarboxylic acid esters of general formula 1 wherein X− and the groups A, R, R1, R2, R3, R3′, R4, and R4′ have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments.
摘要:
Fluorenecarboxylic acid esters of general formula 1 wherein X− and the groups A, R, R1, R2, R3, R3′, R4, and R4′ have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments.
摘要:
Fluorenecarboxylic acid esters of general formula 1 wherein X− and the groups A, R, R1, R2, R3, R3′, R4, and R4′ have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof a medicaments.
摘要:
Fluorenecarboxylic acid esters of general formula 1 wherein X− and the groups A, R, R1, R2, R3, R3′, R4, and R4′ have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments.
摘要:
Fluorenecarboxylic acid esters of general formula 1 wherein X− and the groups A, R, R1, R2, R3, R3′, R4, and R4′ have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments.
摘要:
Flourenecarboxylic acid esters of general formula 1 wherein X− and the groups A, R, R1, R2, R3, R3′, R4, and R4′ have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments.
摘要:
Xanthenecarboxylates of formula 1 wherein: A is a group selected from X− is an anion with a single negative charge; R is hydroxy, methyl, hydroxymethyl, ethyl, —CF3, —CHF2, or fluorine; R1 and R2, which are identical or different, are each C1-C5-alkyl which is optionally substituted by C3-C6-cycloalkyl, hydroxy, or halogen, or R1 and R2 together denote a —C3-C5-alkylene-bridge; and R3, R4, R3′, and R4′, which are identical or different, are each hydrogen, —C1-C4-alkyl, —C4-alkyloxy, hydroxy, —CF3, —CHF2, —CN, —NO2, or halogen, or a physiologically acceptable salt thereof, processes for preparing, them and their use in pharmaceutical compositions.
摘要:
A pharmaceutical composition comprising: (a) a compound of formula 1 wherein X31 is an anion with a single negative charge; and (b) a PDE IV inhibitor, or an enantiomer, mixture of enantiomers, racemate, solvate, or hydrate thereof, processes for preparing them, and their use in the treatment of respiratory complaints.
摘要:
A pharmaceutical composition comprising a compound of formula 1 wherein X− is an anion with a single negative charge, and a betamimetic, optionally together with a pharmaceutically acceptable excipient, the compound of formula 1 and the betamimetic optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of respiratory tract diseases.
摘要:
A pharmaceutical composition comprising a compound of formula 1 wherein X− is an anion with a single negative charge, and a betamimetic, optionally together with a pharmaceutically acceptable excipient, the compound of formula 1 and the betamimetic optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of respiratory tract diseases.